LC-MS/MS Validation Analysis of Trastuzumab Using dSIL Approach for Evaluating Pharmacokinetics
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Budhraja, Rohit H. | - |
dc.contributor.author | Shah, Milin A. | - |
dc.contributor.author | Suthar, Mahendra | - |
dc.contributor.author | Yadav, Arun | - |
dc.contributor.author | Shah, Sahil P. | - |
dc.contributor.author | Kale, Prashant | - |
dc.contributor.author | Asvadi, Parisa | - |
dc.contributor.author | Arasu, Mariadhas Valan | - |
dc.contributor.author | Al-Dhabi, Naif Abdullah | - |
dc.contributor.author | Park, Chun Geon | - |
dc.contributor.author | Kim, Young-Ock | - |
dc.contributor.author | Kim, Hak Jae | - |
dc.contributor.author | Agrawal, Y. K. | - |
dc.contributor.author | Krovidi, Ravi. K. | - |
dc.date.accessioned | 2021-08-11T16:44:43Z | - |
dc.date.available | 2021-08-11T16:44:43Z | - |
dc.date.issued | 2016-11 | - |
dc.identifier.issn | 1420-3049 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/8629 | - |
dc.description.abstract | Quantitative targeted proteomics based approaches deploy state-of-the-art Liquid chromatography tandem mass spectrometry LC-MS technologies and are evolving as a complementary technique to standard ligand-binding based assays. Advancements in MS technology, which have augmented the specificity, selectivity and sensitivity limits of detection and freedom from antibody generation, have made it amicable towards various clinical applications. In our current work, a surrogate peptide based quantitative proteomics assessment is performed by selecting specific signature peptides from the complementary determining region CDR region of trastuzumab (Herclon (R), Roche products in India). We developed a double Stable Isotope Label (dSIL) approach by using two different surrogate peptides to evaluate the proteolytic digestion efficiency and accurate quantification of the target analyte peptide of Herclon (R) in human serum. Method validation experiments were meticulously performed as per bioanalytical method validation guidelines. The dSIL approach, using an LC-MS/MS based quantification assay demonstrated good linearity over a range of 5-500 mu g/mL of Herclon (R), and validation experimental data is in compliance with bioanalytical regulatory guidelines. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Multidisciplinary Digital Publishing Institute (MDPI) | - |
dc.title | LC-MS/MS Validation Analysis of Trastuzumab Using dSIL Approach for Evaluating Pharmacokinetics | - |
dc.type | Article | - |
dc.publisher.location | 스위스 | - |
dc.identifier.doi | 10.3390/molecules21111464 | - |
dc.identifier.scopusid | 2-s2.0-84993990092 | - |
dc.identifier.wosid | 000389918200046 | - |
dc.identifier.bibliographicCitation | Molecules, v.21, no.11 | - |
dc.citation.title | Molecules | - |
dc.citation.volume | 21 | - |
dc.citation.number | 11 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Biochemistry & Molecular Biology | - |
dc.relation.journalResearchArea | Chemistry | - |
dc.relation.journalWebOfScienceCategory | Biochemistry & Molecular Biology | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Multidisciplinary | - |
dc.subject.keywordPlus | BREAST-CANCER | - |
dc.subject.keywordPlus | PEPTIDE | - |
dc.subject.keywordPlus | QUANTIFICATION | - |
dc.subject.keywordPlus | ONCOGENE | - |
dc.subject.keywordPlus | ASSAY | - |
dc.subject.keywordPlus | HER2 | - |
dc.subject.keywordAuthor | trastuzumab | - |
dc.subject.keywordAuthor | LC-MS/MS | - |
dc.subject.keywordAuthor | dSIL | - |
dc.subject.keywordAuthor | pharmacokinetics | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.